Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D J Graham

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Clinical Therapeutics|February 25, 2000
Antibiotics and Clostridium difficile diarrhea in the ambulatory care settingD G Levy, A Stergachis, L V McFarland, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1994
Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitorsV W Byrnes, E A Emini, W A Schleif, et al.
American Journal of Epidemiology|February 1, 1988
Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three yearsF E Shaw, D J Graham, H A Guess, et al.
Journal of Virology|December 1, 1996
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitorJ H Condra, D J Holder, W A Schleif, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Clinical Therapeutics|February 25, 2000
Antibiotics and Clostridium difficile diarrhea in the ambulatory care settingD G Levy, A Stergachis, L V McFarland, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1994
Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitorsV W Byrnes, E A Emini, W A Schleif, et al.
American Journal of Epidemiology|February 1, 1988
Postmarketing surveillance for neurologic adverse events reported after hepatitis B vaccination. Experience of the first three yearsF E Shaw, D J Graham, H A Guess, et al.
Journal of Virology|December 1, 1996
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitorJ H Condra, D J Holder, W A Schleif, et al.
Pageof 8